These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20583854)

  • 1. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Decha P; Intharathep P; Udommaneethanakit T; Sompornpisut P; Hannongbua S; Wolschann P; Parasuk V
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):29-36. PubMed ID: 20583854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Balzarini J; Gago F
    J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
    Treesuwan W; Hannongbua S
    J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
    Ribone SR; Quevedo MA; Madrid M; Briñón MC
    J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
    Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
    J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L; Betancor G; Matamoros T
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
    Thammaporn R; Ishii K; Yagi-Utsumi M; Uchiyama S; Hannongbua S; Kato K
    Biol Pharm Bull; 2016; 39(3):450-4. PubMed ID: 26934936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
    Minkara MS; Davis PH; Radhakrishnan ML
    Proteins; 2012 Feb; 80(2):573-90. PubMed ID: 22095671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Rattanabunyong S; Choengpanya K; Suwattanasophon C; Kiriwan D; Wolschann P; Lamtha T; Shaikh AR; Rattanasrisomporn J; Choowongkomon K
    J Vet Sci; 2023 Sep; 24(5):e67. PubMed ID: 38031646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
    Liu J; He X; Zhang JZ
    J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J; Stammers DK
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.
    Smith MB; Rader LH; Franklin AM; Taylor EV; Smith KD; Smith RH; Tirado-Rives J; Jorgensen WL
    Bioorg Med Chem Lett; 2008 Feb; 18(3):969-72. PubMed ID: 18166457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.